Eltrombopag ITP denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues an Experimental Denial for Eltrombopag in ITP

An "experimental or investigational" denial in this context is almost always a classification error. Eltrombopag (Promacta) holds full FDA approval for chronic immune thrombocytopenia (ITP) in adults and pediatric patients meeting the criteria described in the label. UHC's system may generate an experimental denial when the billing code combination, the patient's age bracket, or the specific ITP subtype (for example, secondary ITP or ITP in a patient with a concurrent condition) does not map cleanly to an approved coverage pathway in the plan's claims logic. It can also arise when a newer formulation or dosage form is reviewed under an older policy.

## Why This Denial Is Appealable

FDA approval is the baseline legal standard for a drug not being experimental. A plan that labels an FDA-approved drug "experimental" for its approved indication is making an error of fact, and federal law gives you the tools to correct it. Under ACA §2719, non-grandfathered plans must offer internal appeal and independent external review. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review with written explanation. You typically have 180 days from the denial notice to file internally. If the internal appeal is denied, external review must generally be requested within 4 months of the final internal denial. An expedited review path is available when there is urgent clinical need.

## Concrete Appeal Steps

1. Obtain the FDA-approved package insert for eltrombopag — it documents the exact approved indication, including ITP. Attach it to every appeal submission. 2. Request UHC's experimental/investigational criteria — the plan must disclose the specific standard it applied. 3. File an internal appeal citing the FDA approval as direct rebuttal evidence. 4. Escalate to external review if the internal appeal is denied — an independent reviewer is required to apply accepted standards of care, not just the plan's internal policy.

## Documentation to Gather

• FDA approval documentation: the current prescribing label confirming the ITP indication.
• Diagnosis records: hematology notes, platelet count history, and ITP classification supporting the on-label use.
• Prescriber letter: the treating physician should confirm the prescription is for the FDA-approved indication, cite the relevant professional society guidance (such as that from ASH — the American Society of Hematology), and explain why the use is standard of care, not experimental.
• Published guideline reference: a citation to the applicable ASH clinical practice guideline for ITP, without quoting specific statistics, showing eltrombopag is a recognized standard treatment option.

## Criteria-Mapping Structure

Copy the exact language from UHC's experimental/investigational policy, then rebut each element with documented evidence:

| Policy Criterion | Rebuttal Evidence | |---|---| | FDA approval for stated indication | FDA-approved label, indicated use section | | Recognition in medical literature / guidelines | ASH guideline citation confirming standard-of-care status | | Patient meets on-label criteria | Diagnosis and treatment history from chart |

Consult the FDA-approved prescribing information for eltrombopag and the UHC coverage policy for TPO-RAs or ITP treatments to match every criterion precisely to your documentation.